View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 27, 2021updated 23 Nov 2021 5:25am

NiKang Therapeutics secures $200m in Series C funding 

NiKang Therapeutics secures $200m in Series C funding round to develop small molecules for difficult-to-drug targets in cancer.

NiKang Therapeutics has secured $200m in a Series C funding round to develop new small molecules for difficult-to-drug targets in oncology indications.

The financing round was led by Cormorant Asset Management, HBM Healthcare Investments and Octagon Capital Advisors.

Several other companies took part, including the latest investors EcoR1 Capital, Perceptive Advisors, Wellington Management, Ally Bridge Group and Pavilion Capital among others.

All the present investors of NiKang, which includes CBC Group, RTW Investments, Lilly Asia Ventures, Matrix Partners China and Casdin Capital, participated in the financing round.

As part of the funding, Viela Bio former CEO and chairman Bing Yao and Octagon Capital Advisors founder and chief investment officer Ting Jia will join NiKang’s board of directors.

The company noted that the proceeds will be utilised to drive its lead drug candidates into clinical development, boost its pipeline and support drug discovery programmes.

NiKang Therapeutics co-founder, president and CEO Zhenhai Gao said: “We are thrilled to have such an outstanding group of investors as our shareholders. Their support of our vision allows us to build the world’s leading precision oncology company.

“We are now well-positioned to rapidly advance our pipeline into the clinic, including our differentiated HIF-2 alpha inhibitor, and to bring our company to the next level of growth.”

In a separate development, Singapore-based Esco Lifesciences has raised $200m in a Series A and Crossover funding round to build an innovation hub in Boston, US, which will focus on cell and gene therapy tools and technologies.

The funding round was led by Vivo Capital and Novo Holdings while participation included new investors China Investment and domestic investor EDBI among others.

Esco Lifesciences chairman and CEO XQ Lin said: “This is a significant milestone for the company as we embark on our Esco 3.0 transformation, which primarily involves strategic bolt-on M&A and expedited expansion in China, our priority market, to maintain the strong revenue growth we have achieved over the last decade.”

The proceeds from the Series A funding will also be used to boost its research and development (R&D) and in-licensing activities to develop and market new life science research tools in emergent areas.

This will aid in vital scientific discoveries and could enable the development of diagnostics and medicines for the future, Esco Lifesciences noted.

Related Companies

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU